CRL
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 15 ▲ Ro Khanna bought $1,001 - $15,000, last disclosed Jun 11
- Jun 29 ▼ 1 insider sell $16.9M at $225.00
- Jun 30 The RIVER FARM, LLC v. HALL COUNTY BOARD OF TAX ASSESSORS
- Aug 5 to Aug 25 ▼ 7 days of insider sells: $25.7M by 6 insiders, avg $282.79
- Aug 6 ▲ JP Morgan upgrades
- Sep 30 ▲ 1 insider buy $3.0K at $297.43
- Sep 30 ▲ 8 funds open new positions (13F)
- Sep 30 ▼ Short interest jumps 29.1% to 2.88M
- Oct 5 ▼ 1 insider sell $302.6K at $308.44
- Oct 21 to Oct 22 ▼ 2 days of insider sells: $9.2M by 2 insiders, avg $349.54
- Nov 4 ▲ Charles River reported Q3 2026 non-GAAP EPS of $3.09, beating the $2…
- Nov 4 ▲ Earnings: CRL Q3 2026 Earnings: EPS $3.09 (+2.9% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider bought $3.0K at an average $297.43. 6 insiders sold $52.1M. Price is 13% above their cost.
- InstitutionsMIXED
Q3 2026: 52 added (8 new), 40 trimmed or exited. Largest new: Artisan Partners Limited Partnership $42.1M, Natixis $12.4M.
- AnalystsBULLISH
17 of 22 rate it Buy or better. Median target $375.00 (+12%).
- Short sellersSTEADY
Short interest +5.4% to 2.99M shares. 2.2 days to cover, ≈6.2% of shares.
- TrendUPTREND
8% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 4.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | ADD | $1.8B |
| Invesco Ltd. | TRIM | $546.5M |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | ADD | $299.1M |
| DIMENSIONAL FUND ADVISORS LP | TRIM | $275.4M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | $258.7M |
| Allspring Global Investments Holdings, LLC | TRIM | $254.6M |
| Neuberger Berman Group LLC | TRIM | $184.8M |
| JPMORGAN CHASE & CO | ADD | $130.3M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
22 analystsPrice is inside the target range. Median implies +12%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 5, 2026 | UBS MAINTAIN | Buy |
| Nov 5, 2026 | RBC Capital MAINTAIN | Outperform |
| Nov 5, 2026 | Barclays MAINTAIN | Overweight |
| Nov 5, 2026 | Evercore ISI Group MAINTAIN | Outperform |
| Oct 13, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Sep 28, 2026 | Jefferies MAINTAIN | Buy |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Knell Michael Gunnar SVP, Finance and CAO Nov 6, 2026 | TAX W/H | $203.1K |
FOSTER JAMES C Director Oct 22, 2026 | SELL | $8.4M |
FOSTER JAMES C Director Oct 22, 2026 | EXERCISE | $5.9M |
Parisotto Shannon M CEVP, Disc & Safety Assessment Oct 21, 2026 | EXERCISE | $526.9K |
Parisotto Shannon M CEVP, Disc & Safety Assessment Oct 21, 2026 | SELL | $742.5K |
Parisotto Shannon M CEVP, Disc & Safety Assessment Oct 5, 2026 | SELL | $302.6K |
Parisotto Shannon M CEVP, Disc & Safety Assessment Oct 5, 2026 | EXERCISE | $204.5K |
Coleman Glenn EVP & Chief Financial Officer Sep 30, 2026 | BUY | $3.0K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
17 filings · 4 bullish · 1 bearish · 1 mixed · 11 neutral- NEUTRAL SC 13GNov 16, 2026
T. Rowe Price Associates disclosed a 6.3% passive stake in Charles River Laboratories via Schedule 13G, holding 3,010,619 shares as of September 30, 2026. This is a new 5%+ filing, indicating a meaningful passive position in the company following its Q3 earnings beat and raised guidance.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 10, 2026
Invesco Ltd. filed an amended Schedule 13G for Charles River Laboratories, reporting beneficial…
Invesco's stake is below 5% and declining, indicating reduced conviction. Monitor for further reductions or a potential exit. The passive 13G status suggests no activist intent.
- NEUTRAL 8-KNov 9, 2026
Charles River Laboratories announced it has entered definitive agreements to acquire Frontage…
Monitor the closing timeline and regulatory approvals in Hong Kong and the Cayman Islands. The acquisition is expected to be neutral to non-GAAP EPS in 2027, so any guidance revision or update on…
- NEUTRAL SC 13G/ANov 5, 2026
FMR LLC (Fidelity) filed an amended Schedule 13G for Charles River Laboratories, reporting…
Fidelity's passive stake is unchanged after the Q3 earnings beat, suggesting no rebalancing or conviction shift. Monitor future 13G filings for any material increase or decrease that could signal a…
All CRL filing & press-release reports (17)
- SC 13G reportNov 16, 2026
- SC 13G/A reportNov 10, 2026
- 8-K reportNov 9, 2026
- SC 13G/A reportNov 5, 2026
- 8-K reportNov 4, 2026
- CLUSTER reportOct 26, 2026
- 144 reportOct 22, 2026
- INST-CLUSTER reportOct 21, 2026
- 8-K reportSep 24, 2026
- CLUSTER reportAug 27, 2026
- CLUSTER reportAug 20, 2026
- CLUSTER reportAug 13, 2026
- CLUSTER reportAug 11, 2026
- CLUSTER reportAug 10, 2026
- 8-K reportAug 5, 2026
- 8-K reportMay 7, 2026
- 8-K reportFeb 25, 2026